# PCOS Gets a New Name: PMOS
The medical community is renaming polycystic ovary syndrome to metabolic ovarian syndrome, or PMOS. Doctors say the shift better reflects what the condition actually is and how it develops.
The current name, PCOS, misleads patients and clinicians alike. Many people with the condition don't have cysts on their ovaries at all. The name also centers ovarian features while overlooking the metabolic dysfunction that drives the disorder. This confusion delays diagnosis and fragmentation care across specialties.
PMOS emphasizes the metabolic root of the condition. The syndrome involves insulin resistance, inflammation, and hormonal imbalance that affects ovarian function. Roughly 70 to 80 percent of people with PCOS struggle with insulin resistance, yet many never receive metabolic screening or support. The new name signals that treating the underlying metabolic problem matters as much as addressing ovarian symptoms.
The rename has support from reproductive endocrinologists and metabolic health specialists. They argue the change removes barriers to early detection. Patients with irregular periods or fertility struggles often see gynecologists first, who may miss metabolic warning signs. A metabolic framework encourages doctors to order appropriate testing, refer to nutritionists, and consider lifestyle interventions that actually address root causes.
This shift aligns with how practitioners already treat the condition. Lifestyle changes including structured exercise, dietary modifications, and weight management improve insulin sensitivity and reduce symptoms. Metformin, a medication that targets insulin resistance, remains a first-line treatment. These approaches target metabolism, not just ovarian cysts.
The name change also acknowledges that PMOS affects people across their lifespan. Metabolic dysfunction often precedes ovarian symptoms by years. Understanding PMOS as a metabolic disorder helps younger people recognize early warning signs and older patients understand